You are here

Angew Chem Int Ed Engl DOI:10.1002/anie.201603797

Discovery of a Highly Selective Glycogen Synthase Kinase-3 Inhibitor (PF-04802367) That Modulates Tau Phosphorylation in the Brain: Translation for PET Neuroimaging.

Publication TypeJournal Article
Year of Publication2016
AuthorsLiang, SH, Chen, JMichael, Normandin, MD, Chang, JS, Chang, GC, Taylor, CK, Trapa, P, Plummer, MS, Para, KS, Conn, EL, Lopresti-Morrow, L, Lanyon, LF, Cook, JM, Richter, KEG, Nolan, CE, Schachter, JB, Janat, F, Che, Y, Shanmugasundaram, V, Lefker, BA, Enerson, BE, Livni, E, Wang, L, Guehl, NJ, Patnaik, D, Wagner, FF, Perlis, R, Holson, EB, Haggarty, SJ, Fakhri, GEl, Kurumbail, RG, Vasdev, N
JournalAngew Chem Int Ed Engl
Volume55
Issue33
Pages9601-5
Date Published2016 Aug 08
ISSN1521-3773
Abstract

Glycogen synthase kinase-3 (GSK-3) regulates multiple cellular processes in diabetes, oncology, and neurology. N-(3-(1H-1,2,4-triazol-1-yl)propyl)-5-(3-chloro-4-methoxyphenyl)oxazole-4-carboxamide (PF-04802367 or PF-367) has been identified as a highly potent inhibitor, which is among the most selective antagonists of GSK-3 to date. Its efficacy was demonstrated in modulation of tau phosphorylation in vitro and in vivo. Whereas the kinetics of PF-367 binding in brain tissues are too fast for an effective therapeutic agent, the pharmacokinetic profile of PF-367 is ideal for discovery of radiopharmaceuticals for GSK-3 in the central nervous system. A (11) C-isotopologue of PF-367 was synthesized and preliminary PET imaging studies in non-human primates confirmed that we have overcome the two major obstacles for imaging GSK-3, namely, reasonable brain permeability and displaceable binding.

DOI10.1002/anie.201603797
Pubmed

http://www.ncbi.nlm.nih.gov/pubmed/27355874?dopt=Abstract

Alternate JournalAngew. Chem. Int. Ed. Engl.
PubMed ID27355874
PubMed Central IDPMC4983481
Grant ListK01 DA038000 / DA / NIDA NIH HHS / United States